

FOR IMMEDIATE RELEASE

November 2, 2000

CONTACTS:
David Bupp,
President &CEO
Brent L. Larson
VP Finance/CFO

E-MAIL:
info@neoprobe.com
HOME PAGE:
www.neoprobe.com
614 793 7500

NEOPROBE ANNOUNCES QUARTERLY EARNINGS AND RECORD YEAR-TO-DATE RESULTS

DUBLIN, OHIO -- November 2, 2000 -- Neoprobe Corporation (OTCBB:NEOP) today announced continued profitability improvement and a 66% revenue increase for the third quarter of fiscal year 2000. Revenue for the third quarter was \$2.3 million compared to \$1.4 million for the same period in 1999.

Neoprobe's net income for the third quarter was \$504,000 (\$0.02 per share) compared to a net loss of \$1.7 million (\$0.07 per share) in the comparable prior year quarter. Total operating expenses for the quarter were reduced by 76% to \$660,000 in 2000 compared to \$2.8 million in operating expenses in the third quarter of 1999.

For the first nine months of fiscal year 2000, revenues were \$6.9 million compared to \$5.2 million for the first nine months of 1999, an increase of 32%. Neoprobe's net income for the first nine months was a record \$1.1 million compared to a net loss of \$4.4 million in 1999.

"Third quarter results continue to showcase the positive effects of Neoprobe's distribution alliance entered into at the end of the third quarter of 1999 as well as the Company's expense control measures initiated in prior years," said David Bupp, Neoprobe's President & CEO. "The effect of outsourcing marketing responsibilities has more than offset the decline in gross margins from selling our products on a wholesale basis to the distributor. As a result, Neoprobe's net income is 22% of the Company's revenues for the quarter. We anticipate that fourth quarter results will be consistent with the positive trend experienced in the second and third quarters."

"Surgeons at the recent American College of Surgeons (ACS) were enthusiastic about the newly launched gamma detection probe tips and their companion disposable products. In addition, an enhanced version of the neo2000® control unit, originally launched in 1998, was introduced. The products showcased at the ACS demonstrate Neoprobe's commitment to be the innovative leader in gamma guided surgery," said Bupp.

The Company also reported that during the third quarter NuRigs, Ltd., who has licensed development rights to Rigscan CR, received a response to their regulatory submission to commence clinical evaluation of the humanized version of Rigscan CR. The regulatory agencies have requested additional preclinical testing of the humanized version of Rigscan CR before authorizing the commencement of patient studies. NuRigs expects amended regulatory submissions will be made in second quarter 2001 and the clinical studies will be authorized shortly thereafter. Neoprobe and NuRigs have agreed to extend NuRigs' license option in exchange for additional financial consideration from NuRigs.

In addition, Neoprobe reported that the Company and researchers at the University of California, San Diego (UCSD) have been evaluating a lymphatic agent for use with sentinel lymph node mapping. The agent is being developed by UCSD and is licensed exclusively to Neoprobe. Preclinical testing has been completed and a regulatory submission in the form of a physician's IND (Investigational New Drug) is being finalized for submission in late fourth quarter 2000. It is anticipated that the Phase I clinical studies will begin in early first quarter 2001.

In summary, Bupp said, "Neoprobe's third quarter financial results were continuing affirmation of Neoprobe's core business strategy. In addition, the company and its partners made progress in preparing to begin clinical evaluation of two potential recurring revenue products."

NEOPROBE CORPORATION

CONDENSED BALANCE SHEETS

	(Unaudited)	
	September 30, 2000	December 31, 1999
Assets		
Cash and cash equivalents	\$ 3,270,861	\$ 4,882,537
Other assets	3,231,801	5,440,032
Total assets	\$ 6,502,662	\$ 10,322,569
Liabilities and stockholders' equity (deficit)		
Liabilities to preferred stockholder	\$ -	\$ 3,745,536
Other liabilities	1,060,488	2,916,052
Deferred revenue	3,200,000	3,800,000
Stockholders' equity (deficit)	2,242,174	(139,019)
Total liabilities and stockholders' equity (deficit)	\$ 6,502,662	\$ 10,322,569

CONDENSED STATEMENTS OF OPERATIONS

	Three Months Ended		Nine Months
	(Unaudited)		(Unaudited)
	September 30, 2000	September 30, 1999	September 30, 2000
Revenues	\$ 2,324,991	\$ 1,400,785	\$ 6,892,461
Cost of goods sold	1,230,742	468,553	3,512,767
Gross margin	1,094,249	932,232	3,379,694
Operating expenses:			
Research and development	60,266	77,807	435,620
Marketing and selling	42,397	1,623,874	205,373
General and administrative	557,330	1,077,589	1,794,222
Losses related to subsidiaries in liquidation	-	-	-
Total operating expenses	659,993	2,779,270	2,435,215
Income (loss) from operations	434,256	(1,847,038)	944,479
Other income (expenses), net	96,130	166,217	198,358
Net income (loss) before income taxes	530,386	(1,680,821)	1,142,837
Income taxes	26,296	-	26,296
Net income (loss)	504,090	(1,680,821)	1,116,541
Conversion discount on preferred stock	-	-	-
Accretion to potential redemption value	-	1,804,225	-
Preferred stock dividend requirements	-	51,786	-
Conversion loss on retirement of preferred stock	-	-	764,668
Income (loss) attributable to common stockholders	\$ 504,090	\$ (3,536,832)	\$ 351,873
Income (loss) per common share:			
Basic	\$ 0.02	\$ (0.15)	\$ 0.01
Diluted	\$ 0.02	\$ (0.15)	\$ 0.01

Statements in this news release which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's limited revenues, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and exclusive distributor, uncertainty of market acceptance, competition, limited marketing and manufacturing experience, and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.